Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.81M Buy
45,186
+2,961
+7% +$347K 0.48% 41
2026
Q1
$5.08M Buy
42,225
+1,059
+3% +$122K 0.49% 41
2025
Q4
$4.33M Buy
41,166
+11
+0% +$1.03K 0.42% 49
2025
Q3
$3.45M Buy
41,155
+8,796
+27% +$724K 0.35% 56
2025
Q2
$2.56M Buy
32,359
+121
+0.4% +$9.62K 0.28% 73
2025
Q1
$2.89M Buy
32,238
+2,751
+9% +$257K 0.33% 64
2024
Q4
$2.93M Buy
29,487
+2,254
+8% +$232K 0.33% 68
2024
Q3
$3.09M Buy
27,233
+12,057
+79% +$1.43M 0.37% 69
2024
Q2
$1.88M Buy
15,176
+844
+6% +$109K 0.38% 60
2024
Q1
$1.89M Buy
14,332
+2,068
+17% +$255K 0.38% 62
2023
Q4
$1.34M Sell
12,264
-1,967
-14% -$204K 0.23% 50
2023
Q3
$1.47M Buy
+14,231
New +$1.53M 0.48% 40

Other funds holding MRK

Norden Group's MRK Position: Q2 2026 in Review

Norden Group increased its Merck (MRK) stake by 7% in Q2 2026, buying an estimated $347K and bringing the position to 45,186 shares worth $5.81M. The position accounts for 0.48% of the portfolio, ranked #41.

Norden Group first reported a position in MRK in Q3 2023 and has held it in 12 quarters since. 1,830 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Norden Group held 45,186 shares of Merck worth $5.81M as of Q2 2026.
  • Norden Group bought 2,961 Merck shares in Q2 2026, an estimated $347K.
  • Merck made up 0.48% of Norden Group's portfolio in Q2 2026, its #41 holding.
  • Norden Group first reported a position in Merck in Q3 2023 and has held it in 12 quarters since.
  • 1,830 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Norden Group's 13F filing for Q2 2026, filed 29 Jul 2026.